Abstract: The minimum error entropy (MEE) criterion closely relies on the quadratic information potential (QIP) estimates of Renyi’s entropy. Nevertheless, the ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

ABSTRACT: Artificial deep neural networks (ADNNs) have become a cornerstone of modern machine learning, but they are not immune to challenges. One of the most significant problems plaguing ADNNs is ...

The recursion depth limit in the descriptor parser is enforced after the full parse has already completed, which defeats its protective purpose. Specifically, the check is performed only after parser: ...

Acquisition strengthens QIAGEN’s presence in the rapidly growing single-cell market, accelerating growth across its industry-leading Sample technologies portfolio Parse provides Evercode, a highly ...

A menacing 50-degree slope and 9,000 feet straight down: that’s the terrain American mountaineer Jim Morrison tackled when he became the first person to ski the most difficult route on Everest, the ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

The original version of this story appeared in Quanta Magazine. If you want to solve a tricky problem, it often helps to get organized. You might, for example, break the problem into pieces and tackle ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. It's common for clinical-stage biotech companies to post net ...